The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 36, No. 3, pp. 433-436. DOI 10.1345/aph.1A139
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jeffery, S.
Right arrow Articles by Vitagliano, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jeffery, S.
Right arrow Articles by Vitagliano, G

Research Articles

Gabapentin for hot flashes in prostate cancer

SM Jeffery, JJ Pepe, LM Popovich, and G Vitagliano

OBJECTIVE: To report a case of successful treatment of refractory hot flashes with gabapentin in a patient with prostate cancer who was receiving combination antiandrogen and gonadotropin hormone-releasing hormone (GnRH) analog therapy. CASE SUMMARY: A 70-year-old white man with a history of advancing prostate cancer experienced disabling hot flashes from combination therapy with the antiandrogen bicalutamide and the GnRH analog goserelin acetate. He failed to respond to clonidine 0.1 mg twice daily, megestrol acetate 40 mg/d, diethylstilbestrol 1 mg/d, and venlafaxine 25 mg twice daily. The patient was then treated with gabapentin 600 mg once daily, at which time he experienced near-complete resolution of his symptoms. DISCUSSION: This case supports a previous report of the marked improvement in severity and duration of hot flashes associated with antiandrogen or GnRH analog therapy in prostate cancer. The mechanism by which gabapentin reduces hot flashes is unknown. CONCLUSIONS: Hot flashes resulting from antiandrogen or GnRH analog therapy are often difficult to treat and leave many patients disabled. Gabapentin has been shown to markedly reduce the severity, frequency, and duration of these hot flashes. Controlled trials are necessary to evaluate gabapentin against other therapeutic modalities.


This article has been cited by other articles:


Home page
 The OncologistHome page
C. A. Thompson, T. D. Shanafelt, and C. L. Loprinzi
Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation
Oncologist, October 1, 2003; 8(5): 474 - 487.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. M. Juenke, P. I. Brown, G. A. McMillin, and F. M. Urry
Procedure for the Monitoring of Gabapentin with 2,4,6-Trinitrobenzene Sulfonic Acid Derivatization Followed by HPLC with Ultraviolet Detection
Clin. Chem., July 1, 2003; 49(7): 1198 - 1201.
[Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
L. A. Fitzpatrick and R. J. Santen
Hot Flashes: The Old and the New, What Is Really True?
Mayo Clin. Proc., November 1, 2002; 77(11): 1155 - 1158.
[PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.